Tag:
emerging pharmaceutical markets
Latest Headlines
Latest Headlines
Are emerging markets worth $47B less than pharma expected?
A report from the market research firm GlobalData finds that an unholy convergence of intellectual property worries, price controls and budget cuts is eroding earlier forecasts for emerging-market sales growth.
Roche exec expects 'limited' rebound for pharma
Don't look for a fabulous rebound in drug sales once the patent cliff is past. So says Roche COO Pascal Soriot, who expects a paltry 2% to 3% growth in the U.S. market and stagnant sales in Europe over the next three to 5 years.
Bayer eyes 16% pharma growth on new meds
Bayer CEO Marijn Dekkers is touting Xarelto 's multibillion-dollar prospects again. This time, though, it's just one of four prospective blockbusters drawing Dekkers' praise.
Bayer Healthcare posts big growth in Asia Pacific
Bayer Healthcare said it expects Asia sales to grow to 11 billion euros by 2015, with 6 billion of that coming from the China region.
Pharma group adopts stringent conduct code
In the face of increasing scrutiny of its behavior in emerging markets, a global industry association has rolled out a strict new code of conduct.
A bright side to Europe's woes: U.S., Japan look better
Europe is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to
AZ chief: Emerging markets are tougher than you think
AstraZeneca ( $AZN ) CEO David Brennan ( photo ) talks emerging markets, external collaborations and townhall meetings in a Q&A with Roger Crockett. And, extending the current prefence for bolt-on
Generics market to bulk up by $100B in 5 years
With leading generics makers moving into branded drugs as a hedge against slowing growth of the copycat industry, one might think the knockoff-drug business has transfigured into a tortoise, or
Teva to bulk up in Asia with generics buyouts
Now, it's Teva Pharmaceutical Industries ( $TEVA ) looking eastward for deals. The Israeli-based drugmaker figures the Asian generics market will be hopping over the next several years, with burgeoning
Merck leads 2011's list of job-cutting drugmakers
Perhaps the most persistent trend in the drug business is one management would prefer to discuss only with analysts, and certainly not with the rank-and-file. Once again, a laundry list of pharma
